Academic
Publications
Multifaceted action of Fuzeon as virus–cell membrane fusion inhibitor

Multifaceted action of Fuzeon as virus–cell membrane fusion inhibitor,10.1016/j.bbamem.2011.06.020,Biochimica Et Biophysica Acta-biomembranes,Avraham

Multifaceted action of Fuzeon as virus–cell membrane fusion inhibitor  
BibTex | RIS | RefWorks Download
The viral peptide fusion inhibitor Fuzeon (T-20/DP178/enfuvirtide) is an essential part of the drug combination that has significantly increased the quality of life and life span of many acquired immuno-deficiency syndrome (AIDS) patients. Its development as a drug preceded the elucidation of its precise inhibitory mechanism, as well as its molecular targets. The initial model was that Fuzeon inhibits human immunodeficiency virus (HIV) entry by targeting one site within the viral transmembrane envelope protein. Herein, we describe the emerging discoveries that extend this model towards a multifaceted mechanism for the drug in targeting HIV. This significantly advances the understanding of how viruses enter host cells and opens a new window of opportunity for designing future viral fusion inhibitors.
Journal: Biochimica Et Biophysica Acta-biomembranes - BBA-BIOMEMBRANES , vol. 1808, no. 10, pp. 2352-2358, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.